Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | VDR | P11473 | 2/20 | 0.35 |
| ▸ | THRA | P10827 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9051635 | 1.00 | THRB (0.35) | THRBVDRTHRAKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL9526790 | 0.96 | SMN1; SMN2 (0.36) | KMT2AMEN1SMN1; SMN2HPGDALDH1A1 | |
| Hydrochloric Acid SCHEMBL9523909 | 0.85 | MEN1 (0.38) | KMT2AMEN1SMN1; SMN2ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL9525176 | 0.83 | LMNA (0.37) | KMT2AMEN1SMN1; SMN2HPGDGAA | |
| SCHEMBL9526836 | 0.81 | SMN1; SMN2 (0.50) | KMT2AMEN1SMN1; SMN2HPGDGAA | |
| Hydrochloric Acid SCHEMBL9526084 | 0.77 | HDAC1 (0.35) | KMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL9528889 | 0.77 | TSHR (0.33) | — | |
| Hydrochloric Acid SCHEMBL9525649 | 0.76 | ADRA2A (0.32) | KMT2AMEN1ALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL9523922 | 0.76 | TSHR (0.33) | — | |
| Hydrochloric Acid SCHEMBL9525326 | 0.75 | MEN1 (0.34) | KMT2AMEN1SMN1; SMN2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | claimed |
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | ILAB (KR) | 2023-12-26 | — | — | US | claimed |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2023-03-30 | — | — | US | claimed |
| US-20220395538-A1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC | 2022-12-15 | — | — | US | claimed |
| US-20220370506-A1 | AUGMENTATION OF FIBROBLAST MEDIATED REGENERATION OF INTRAVERTEBRAL DISCS | FIGENE, LLC | 2022-11-24 | — | — | US | claimed |
| EP-4081261-A1 | AUGMENTATION OF FIBROBLAST MEDIATED REGENERATION OF INTRAVERTEBRAL DISCS | Figene, LLC (US) | 2022-11-02 | — | — | EP | claimed |
| EP-4058037-A1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | Figene, LLC (US) | 2022-09-21 | — | — | EP | claimed |
| US-20260115231-A1 | TREATMENT OF CEREBRAL PALSY USING FIBROBLASTS | SPINALCYTE LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12508287-B2 | Treatment of cerebral palsy using fibroblasts | SPINALCYTE LLC (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3699174-B1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | ILAB (KR) | 2025-11-12 | — | — | EP | disclosed |
| US-20240366677-A1 | Aneurysm Treatment by Exosomes | THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-20220351806-A1 | Biomarker Panels for Guiding Dysregulated Host Response Therapy | PRENOSIS ACQUISITION I, LLC | 2022-11-03 | — | — | US | disclosed |
| EP-4081261-A1 | AUGMENTATION OF FIBROBLAST MEDIATED REGENERATION OF INTRAVERTEBRAL DISCS | Figene, LLC (US) | 2022-11-02 | — | — | EP | disclosed |
| EP-4058037-A1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | Figene, LLC (US) | 2022-09-21 | — | — | EP | disclosed |
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | ALK-ABELLÓ, INC. (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022047486-A2 | DENTAL AND PERIODONTAL APPLICATION OF FIBROBLASTS | FIGENE, LLC (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11850230-B2 | Composition for preventing or treating TNF-related diseases, containing novel derivative as active ingredient, and method for inhibiting TNF activity by using same | TNF, NFKBIA, TRAF6 | THRB 3323/4885VDR 541/4885THRA 3586/4885 |
| US-20230099574-A1 | COMPOSITION FOR PREVENTING OR TREATING TNF-RELATED DISEASES, CONTAINING NOVEL DERIVATIVE AS ACTIVE INGREDIENT, AND METHOD FOR INHIBITING TNF ACTIVITY BY USING SAME | TNF, NFKBIA, TRAF6 | THRB 3323/4885VDR 541/4885THRA 3586/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | THRB 3286/4885VDR 885/4885THRA 1945/4885 |
| US-11369566-B2 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | OTC, OAT, MYOC | THRB 3050/4885VDR 2085/4885THRA 2570/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | THRB 3286/4885VDR 885/4885THRA 1945/4885 |
| US-12508287-B2 | Treatment of cerebral palsy using fibroblasts | PGF, CRH, HIF1A | THRB 1275/4885VDR 4543/4885THRA 2656/4885 |
| US-20260115231-A1 | TREATMENT OF CEREBRAL PALSY USING FIBROBLASTS | PGF, FGF2, FGF1 | THRB 622/4885VDR 3316/4885THRA 1697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.